NCT04608110 - A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG

ASTX030

In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7

Trial Locations (1)

Unknown

RECRUITING

Yamagata University Hospital, Yamagata